Technology area: Biotechnology & Pharmaceuticals
24 pending office actions • 20 art units • 24 examiners • 0 of 24 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Children’S Hospital Medical Center has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, Emily Ann Cordas. The portfolio's current activity is limited to 1 distinct art unit, which indicates a very specific technical focus for this pending matter. Emily Ann Cordas is the busiest examiner, as she is responsible for the 1 pending office action.
Because there is only 1 pending office action, Emily Ann Cordas manages the entirety of the company's current pending workload. The concentration of the 1 pending office action within 1 distinct art unit means that prosecution is highly localized. Practitioners should tailor their approach to the specific standards of this 1 distinct art unit and the individual preferences of Emily Ann Cordas to successfully resolve the pending matter.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §101 + other | 3 (12%) |
| §103 only | 4 (17%) |
| §102 only | 1 (4%) |
| §112 only | 1 (4%) |
| Multi-statute (no §101) | 13 (54%) |
| No statute on record | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARSEN, CARL VICTOR | 1 | 69.7% | +19.7% |
| MISHRA, DEEPA | 1 | 28.9% | +35.5% |
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| AMICK, THOMAS RUSSE | 1 | 73.8% | +29.4% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919030 | Systems and Methods for Quantification of Liver Fibrosis with MRI and Deep Learning | TIEU, BENNY QUOC | 121d overdue |
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | REGLAS, GILLIAN CHELSEA | 91d overdue |
| 18250996 | PSEUDOTYPED PARTICLES, MODIFIED CELLS, RELATED COMPOSITIONS, AND RELATED METHODS | O'NEILL, MARISOL ANN | 32d overdue |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | IVICH, FERNANDO NMN | 62d |
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | CHEN, STACY BROWN | 63d |
| 18915716 | METHODS FOR PREDICTING AUTOIMMUNITY POST GENE THERAPY | MISHRA, DEEPA | — |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | — |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | WILSON, MICHAEL C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | CHEN, STACY BROWN | 63d |
| 19063450 | BIOMETRIC-BASED VIDEO GAME CONTROL SYSTEM AND METHODS THEREOF | LARSEN, CARL VICTOR | — |
| 18915716 | METHODS FOR PREDICTING AUTOIMMUNITY POST GENE THERAPY | MISHRA, DEEPA | — |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | — |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | WILSON, MICHAEL C | — |
| 18415949 | INTEIN TECHNOLOGY TO DELIVER ABCA3 LIPID TRANSPORTER FOR ABCA3 DEFICIENCY | LIPPOLIS, ALEXANDRA ROSE | — |
| 18578381 | DIFFERENTIAL CXCR4 EXPRESSION ON HEMATOPOIETIC PROGENITOR CELLS VERSUS STEM CELLS DIRECTS HOMING AND LONG-TERM ENGRAFTMENT | AMICK, THOMAS RUSSE | — |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1638 | 2 |
| 1633 | 2 |
| 3715 | 1 |
| 1657 | 1 |
| 1634 | 1 |
| 1637 | 1 |
| 1699 | 1 |
| 1647 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19063450 | BIOMETRIC-BASED VIDEO GAME CONTROL SYSTEM AND METHODS THEREOF | LARSEN, CARL VICTOR | 3715 | §103 | Non-Final OA | — | Pending | Feb 26, 2025 |
| 18915716 | METHODS FOR PREDICTING AUTOIMMUNITY POST GENE THERAPY | MISHRA, DEEPA | 1657 | §101§103§112 | Non-Final OA | — | Pending | Oct 15, 2024 |
| 18847004 | DELIVERY METHODS USING PLATELETS | MARVICH, MARIA | 1634 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18415949 | INTEIN TECHNOLOGY TO DELIVER ABCA3 LIPID TRANSPORTER FOR ABCA3 DEFICIENCY | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18578381 | DIFFERENTIAL CXCR4 EXPRESSION ON HEMATOPOIETIC PROGENITOR CELLS VERSUS STEM CELLS DIRECTS HOMING AND LONG-TERM ENGRAFTMENT | AMICK, THOMAS RUSSE | 1638 | §102 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18573954 | STRUCTURALLY COMPLETE ORGANOIDS | ROGERS, ERIC JASON | 1699 | §102§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18380877 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEDIATRIC PAIN | STOICA, ELLY GERALD | 1647 | Other | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18473619 | COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME | MONTANARI, DAVID A | 1632 | §101§103Other | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | CHEN, STACY BROWN | 1672 | §102§112 | Final Rejection | 63d | Pending | Aug 11, 2023 |
| 18224735 | VECTOR SYSTEMS AND METHODS OF USING SAME | GIBBS, TERRA C | 1653 | §112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18272176 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | CHONG, YONG SOO | 1623 | §103§112 | Final Rejection | — | Pending | Jul 13, 2023 |
| 18333934 | Microspheres Containing Decellularized Donor Tissue and Their Use in Fabricating Polymeric Structures | BOECKELMAN, JACOB A | 1655 | §103 | Non-Final OA | 62d | Pending | Jun 13, 2023 |
| 18252813 | REFINED USES OF GABA A RECEPTOR MODULATORS IN TREATMENT OF FRAGILE X SYNDROME | WHITE, DENNIS MICHAEL | 1758 | §102§103Other | Final Rejection | — | Pending | May 12, 2023 |
| 18250996 | PSEUDOTYPED PARTICLES, MODIFIED CELLS, RELATED COMPOSITIONS, AND RELATED METHODS | O'NEILL, MARISOL ANN | 1633 | §102§103 | Final Rejection | 32d overdue | Pending | Apr 28, 2023 |
| 18027900 | RAFT CULTURES AND METHODS OF MAKING THEREOF | MIANO, JOSEPH PAUL | 1631 | §103§112 | Final Rejection | — | Pending | Mar 22, 2023 |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | IVICH, FERNANDO NMN | 1678 | §103§112Other | Non-Final OA | 62d | Pending | Jan 31, 2023 |
| 17997264 | Precision Dosing Regimen | GU, QINHUA | 1633 | §103 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17919030 | Systems and Methods for Quantification of Liver Fibrosis with MRI and Deep Learning | TIEU, BENNY QUOC | 2682 | §101 | Non-Final OA | 121d overdue | Pending | Oct 14, 2022 |
| 17755787 | METHODS FOR TREATING DISEASES | MERTZ, PREMA MARIA | 1674 | §102§103§112 | Final Rejection | — | Pending | May 07, 2022 |
| 17634148 | METHODS FOR MAKING ORGANOID COMPOSITIONS | BEHARRY, ZANNA MARIA | 1632 | §101§103§112Other | Non-Final OA | — | Pending | Feb 09, 2022 |
| 17627613 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | PUTTLITZ, KARL J | 1646 | §103 | Final Rejection | — | Pending | Jan 14, 2022 |
| 17617165 | RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N | PATTERSON, SARAH COOPER | 1675 | §103§112 | Non-Final OA | — | Pending | Dec 07, 2021 |
| 17421908 | COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | 91d overdue | Pending | Jul 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChildren's Hospital Medical Center has 24 pending office actions as of October 2026, spread across 20 art units and 24 examiners.
Carl Victor Larsen has the most, with 1 of Children's Hospital Medical Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
